Gemcitabine Clinical Trial
Official title:
Maintenance Versus Observation With 6 Cycles of Gemcitabine Plus Taxol Sequential Gemcitabine Single Agent in Patients With Metastatic Breast Cancer
The primary purpose of our study is to evaluate whether gemcitabine as a single agent is superior to observation in improving progression-free survival (PFS) in patients with metastatic breast cancer (MBC) who achieved disease control with an initial six cycles of PG as their first-line treatment
Status | Recruiting |
Enrollment | 267 |
Est. completion date | December 2017 |
Est. primary completion date | July 2017 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Histologically Confirmed Metastatic, or Recurrent Breast Cancer - Age over 18 Years - ECOG Performance Status 0-2 - Premenopausal or Postmenopausal Breast Cancer Patients With Measurable or Non-Measurable Lesions, Who Are Candidates for Chemotherapy - Life Expectancy = 3 Months - Patients May Have Received Prior Neoadjuvant or Adjuvant Taxane Regimen as Long as it Has Been 12 Months Since Completion of Regimen. - Patients Either May or May Not Have a Prior Anthracycline Containing Regimen. - Prior Hormonal Therapy as a Treatment of Metastatic Disease is Allowed. But Antitumoral Hormonal Therapy Must be Terminated Prior to Enrollment(up to the Date of Randomization) - Prior Radiation Therapy Allowed as Long as < 25% of the Bone Marrow Has Been Treated,and the Patients Must Have Recovered From the Acute Toxic Effects of the Treatment Prior to Study Enrollment.Prior Radiation to the Whole Pelvis is Not Allowed. Prior Radiotherapy Must be Completed 4 Weeks Before Study Entry. - Adequate Bone Marrow Function (= ANC 1,500/ul, = Platelet 100,000/ul, = Hemoglobin 9.0 g/dl) - Adequate Renal Function (= Serum Creatinine 1.5 mg/dl or CCr = 50 ml/Min) - Adequate Liver Function (= Serum Bilirubin 1.5 mg/dl, = AST/ALT x 3 Upper Normal Limit) - No Prior History of Chemotherapy for Metastatic, Recurrent Breast Cancer - Written Informed consent Exclusion Criteria: - Serious Uncontrolled Intercurrent Infections - Serious Intercurrent Medical or Psychiatric Illness, Including Active Cardiac Disease - Pregnancy or Breast Feeding - Second Primary Malignancy(Except Cancer of Cervix or Skin or Other Malignancy Treated at Least 5 Years Previously With no Evidence of Recurrence) - Documented Parenchymal or Leptomeningeal Brain Metastasis - Peripheral Neuropathy = Grade 2 - Prior Treatment With Gemcitabine Will Not be Allowed. - HER-2 Overexpressing Breast Cancer and Concomitant Trastuzumab Treatment is Not Allowed |
Observational Model: Case Control, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
China | Xijing Hospital , Fourth Military Medical University | Xi`an | Shaanxi |
Lead Sponsor | Collaborator |
---|---|
Xijing Hospital | Eli Lilly and Company |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | QoL(quality of life) | the time from enrollment to disease progression or the date of first documented death,whichever comes first,to observe the quality of life in participants,assessed up to 3 years | the time from enrollment to disease progression or the date of first documented death,assessed up to 3 years | Yes |
Primary | PFS | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years | From randomization to disease progression | Yes |
Primary | PFS(progression free survival) | time from the date of randomization until the date of disease progression,assessed up to 3 years | Yes | |
Primary | PFS(progression free survival) | PFS was defined as the time from the date of randomization until the date of disease progression at any site including distant metastasis or second primary tumors or death,assessed up to 3 years | the time from the date of randomization until the date of disease progression,assessed up to 3 years | Yes |
Secondary | OS(overall survival) | the time from date of randomization until the date of first documented death from any cause,assessed up to 3 years | the time from date of randomization until the date of first documented death from any cause,assessed up to 3 years | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00504192 -
A Phase II Study of Gemcitabine With Oxaliplatin as First Line Chemotherapy in Advanced Biliary Tract Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05030077 -
Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma
|
Phase 2 | |
Recruiting |
NCT06156514 -
Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer
|
Phase 3 | |
Completed |
NCT03079427 -
Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma
|
Phase 2 | |
Completed |
NCT01964430 -
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
|
Phase 3 | |
Recruiting |
NCT03373019 -
Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
|
Phase 2 | |
Not yet recruiting |
NCT05647330 -
Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05487443 -
The Efficacy of Chemotherapy Combined With Immunocheckpoint Inhibitors in Advanced Biliary Malignancies
|
Phase 2/Phase 3 | |
Recruiting |
NCT03779464 -
Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the Pancreas
|
Phase 2 | |
Not yet recruiting |
NCT06374914 -
Sequential Intravesical Gemcitabine and Docetaxel for Rescue Therapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer Patients
|
||
Recruiting |
NCT03884205 -
GDPE/CEOPE Compared With CEOPE for Newly Diagnosed Patients With PTCL
|